Research Article

PAC-Mediated AKI Protection Is Critically Mediated but Does Not Exclusively Depend on Cell-Derived Microvesicles

H. Dihazi ¹, K. Schwarze ¹, S. Patschan ², G. A. Müller ¹, O. Ritter ²,
M. Zeisberg ¹ and D. Patschan ²

¹Klinik für Nephrologie und Rheumatologie, Universitätsmedizin Göttingen, Göttingen, Germany

²Zentrum für Innere Medizin 1, Klinikum Brandenburg, Medizinische Hochschule Brandenburg, Brandenburg, Germany

Correspondence should be addressed to D. Patschan; d.patschan@klinikum-brandenburg.de

Received 11 August 2020; Revised 19 February 2021; Accepted 26 February 2021; Published 10 March 2021

Academic Editor: Franca Anglani

Copyright © 2021 H. Dihazi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Acute kidney injury (AKI) significantly worsens the prognosis of hospitalized patients. In recent years, cell-based strategies have been established as a reliable option for improving AKI outcomes in experimental AKI. Our previous studies focused on the so-called proangiogenic cells (PACs). Mechanisms that contribute to PAC-mediated AKI protection include production/secretion of extracellular vesicles (MV, microvesicles). In addition, the cells most likely act by paracrine processes (secretome). The current study evaluated whether AKI may be preventable by the administration of either PAC-derived MV and/or the secretome alone. **Methods.** AKI was induced in male C57/Bl6N mice (8–12 weeks) by bilateral renal ischemia (IRI-40 minutes). Syngeneic murine PACs were stimulated with either melatonin, angiopoietin-1 or -2, or with bone morphogenetic protein-5 (BMP-5) for one hour, respectively. PAC-derived MV and the vesicle-depleted supernatant were subsequently collected and i.v.-injected after ischemia. Mice were analyzed 48 hours later. **Results.** IRI induced significant kidney excretory dysfunction as reflected by higher serum cystatin C levels. The only measure that improved AKI was the injection of MV, collected from native PACs. The following conditions worsened after ischemic renal function even further: MV + Ang-1, MV + BMP-5, MV + melatonin, and MV + secretome + Ang-1. **Conclusion.** Together, our data show that PAC-mediated AKI protection substantially depends on the availability of cell-derived MV. However, since previous data showed improved AKI-protection by PACs after cell preconditioning with certain mediators (Ang-1 and -2, melatonin, BMP-5), mechanisms other than exclusively vesicle-dependent mechanisms must be involved in PAC-mediated AKI protection.

1. Introduction

In-hospital incidences of AKI (Acute Kidney Injury) have been increased over the last 10–15 years. In central Europe, it is being estimated that nearly 15% of all subjects treated in hospitals acquire AKI during the course of the disease [1]. The prognosis however has not significantly been improved since the early 1990s; particularly high mortality rates have been reported in AKI patients with malignancies, sepsis, and dialysis [2]. Thus, clinical and experimental researchers all over the planet strive to identify new strategies for AKI diagnosis and management. Cell-derived therapies have been utilized in experimental AKI; the results are promising. Regarding mesenchymal stem cells (MSCs), even some

clinical trials have been initiated [3]. Another emerging cell population are the so-called induced pluripotent stem cells (iPSCs) [4]. Studies on iPSCs in AKI are rare at the moment and exclusively restricted to animal models [5, 6]. Several other investigations focused on proangiogenic cells (PACs), which for many years were defined as early endothelial progenitor cells [7]. Systemic PAC administration significantly attenuated murine AKI, in both terms, excretory function and renal morphology [8]. There are however certain problems associated with cell-based therapies in AKI in general. Firstly, cell isolation and expansion potentially require several days. Secondly, the exact time point of cell injection remains difficult to predict. Finally, cells, isolated from a certain donor, must be accepted by an individual

suffering from AKI. Therefore, cells, whatever their exact biological characteristics may be, will most likely not be utilized for AKI treatment in a direct manner in the near future. The problems associated with cell-based therapies have been discussed lately [9].

Meanwhile, the mechanisms by which PACs act within the postischemic microenvironment have been elucidated more in detail. In 2012, Cantaluppi and colleagues [10] identified cell-derived microvesicles (MV) to be of critical importance for AKI protection. The administration of MV alone substantially protected animals from AKI. Since the study by Cantaluppi, numerous other investigators reported on kidney-protective roles of certain types of extracellular vesicles, derived from heterogeneous cell types such as mesenchymal stem cells, endothelial colony forming cells, induced pluripotent stem cells, and others [11–18] (Bruno, Zhou, Herrera, Collina, Burger, Zhang, Ranghino, Yuan). Meanwhile, cell-derived vesicles have therefore been accepted as mediators of tissue protection under various circumstances. Several years earlier, Rehman et al. [19] identified a heterogeneous group of humoral factors produced and secreted by PACs (EPCs). It was subsequently argued that a particular group of proteins, described by the term *secretome*, potentially mediates vasomodulatory effects of the cells. Today, the relative roles of MV and secretome in tissue protection are still unknown. We therefore aimed to analyze the effectiveness of both components in murine AKI. The overall goal was to determine which cellular excretory product may possibly be utilized for therapeutic purposes in the future. Some general remarks about the terminology used for describing nature/biology of cell-derived vesicles need to be prepended. In 2018, Théry et al. [20] published a position statement of the International Society for Extracellular Vesicles (ISEV), the “Minimal Information for Studies of Extracellular Vesicles 2018” or MISEV2018. Regarding the detailed discussion provided herein, the vesicular structures employed in our study should most likely be termed as “extracellular vesicles” (EV). We however maintained the term MV (microvesicles) throughout the article.

2. Materials and Methods

2.1. Animals Models. As in previous animal-based studies, all protocols were performed according to the guidelines of the German Institute of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of the University of Göttingen. For all experiments, we employed male C57/Bl6N mice (8–12 weeks old). Mice were bred in the local animal facility of the Göttingen University Hospital. Animals were separately caged with a 12:12 h light-dark cycle and had free access to water and chow throughout the study.

2.2. Surgical Procedures. Anaesthesia was performed with a solution of 300 μ l 6 mg/100 g ketamine hydrochloride plus 0.77 mg/100 of xylazine hydrochloride, applied intraperitoneally. Mice were placed on a heated surgical pad during

the whole procedure. Rectal temperature was permanently maintained at 37°C. The abdominal cavity was opened by a 1.5 cm midlaparotomy. Both kidneys were exposed and clamping of the renal pedicles was performed with microserrafines (Fine Science Tools, Forster City, USA) for 40 minutes, respectively. The clamps were released and a constant volume of MV or SECR containing buffer/medium (isolation of cell-derived microvesicles (MV) and secretome (SECR) from native and preconditioned PACs) was injected into the tail vein and, thus, into the systemic circulation. The abdominal incision was closed with a 4-0 suture and surgical staples. In each experimental group, 10 animals were analyzed. Animals were sacrificed 48 hours later. Euthanization was performed by injecting the threefold dose of anaesthesia, followed by dissecting the diaphragm.

2.3. Isolation of Cell-Derived Microvesicles (MV) and Secretome (SECR) from Native and Preconditioned PACs. Both components, PAC-derived microvesicles (MV) and the secretome (SECR), were isolated from syngeneic murine PACs. The cells were isolated and expanded as described previously in detail [21]. However, we will briefly describe the procedure again. Mouse mononuclear cells (MNCs) were enriched by density gradient centrifugation using Biocoll solution (Biochrom, Berlin, Germany) from peripheral blood and spleen cell extracts. The reason for collecting cells from the two compartments was the intention to maximize the total number of cells available for injection. Mononuclear cells were mixed and, differing to previous protocols in which 4×10^6 cells were used [21], 25×10^6 cells were plated on 6-well culture dishes coated with human fibronectin (Sigma, St Louis, MO) and maintained in endothelial cell medium-2 (EGM-2; Clonetics, Lonza, Walkersville, MD, USA) supplemented with endothelial growth medium (EGM) Single-Quots containing 5% FCS. Four to 5 days later, cultured PACs were identified by the uptake of DiI-labeled acetylated low density lipoprotein (acLDL) (Invitrogen, Carlsbad, CA, USA) and simultaneous binding of FITC-labeled BS-1 lectin (BS-1) (Sigma Diagnostics, St. Louis, MO). SECR: at the day of surgery (5–6 days after initial cell seeding), PACs were incubated with one of the following substances: angiotensin-1 (250 ng/mL); angiotensin-2 (250 ng/mL); bone morphogenetic protein-5 (BMP-5—100 ng/mL); melatonin (5 μ Mol/L). Incubations were performed for 1 hour at 37°C, and the mediators were applied in fresh EGM-2, respectively. Supernatants were collected and filtered (pore size 0.8 μ m). Filtrates were subsequently centrifuged for 6 minutes at 13,000 rpm auf (Vivaspin 500 100,000 MWCO—Satorius VS0142). For SECR injection experiments, every mouse received 100 μ L per tail vein injection. MV: after supernatant filtration (pore size 0.8 μ m), cell-derived microvesicles were collected using the ExoEasy Kit (Qiagen 76064) according to the manufacturer’s protocol. Finally, a total volume of MV-containing eluate was applied in an individual mouse per tail vein injection.

2.4. Verification of MV Isolation. In order to verify the presence of MV after the previous procedure, supernatant was initially filtered using a filter of 0.8 μ M pore size. The

next steps were performed with the ExoEasy Kit by Qiagen® (76064). Two-point 5 ml of filtrate was mixed with 2.5 ml of XBP buffer, followed by inversion (5 times). The solution was centrifugated for 1 minute at 500 g using an exoEasy spin column. The column was washed once with 10 ml of XWP buffer, followed by another centrifugation step (5 minutes at 500 g). Next, 400 μ l of XE buffer was applied on the column, followed by incubation for 1 minute and centrifugation for 5 minutes at 500 g. The last step was repeated once. The eluate was transferred in Vivaspin 500 tubes and centrifugated for 6 minutes at 13,000 rpm. All the following steps were performed with the Exosome ELISA Complete KIT for CD63 detection by System Biosciences® (EXOEL-CD63A-1). The analyses were performed according to the manufacturer's instructions. We therefore describe the procedure in a brief manner. The eluate was incubated with 200 μ l of exosome binding buffer for 20 minutes at 37°C. A 96-well Elisa plate was filled with 50 μ l per well, and incubation was performed at 37°C overnight. Three washing steps followed. Anti-CD63 was added (1:100) for 1 hour at RT, followed by three further washing steps. Secondary incubation was performed with goat anti-rabbit HRP (1:5,000) for 1 hour at RT. Wells were washed again three times. Next, 50 μ l of TMB (3,3',5,5'-tetramethylbenzidine) was added for 45 minutes at RT. The reaction was stopped with 50 μ l of stop buffer per well. Wells were subsequently analyzed at 45 nm.

2.5. Histology and Immunofluorescence Staining of Tissue Sections. The following methodical approaches were used for the quantification of fibrosis (Masson trichrome) and of endothelial α -Smooth Muscle Actin (α SMA) or α -Tubulin (α T) expression. All analyses were performed using ImageJ® software. Fibrosis: the cortical area of every kidney was documented, and areas not being covered by tissue were not considered. The total area of analysis was quantified by the total number of pixels. All pixels within a particular color range (here: green) were quantified and related to the total pixel number of interest. Results were given as percent of the total number of image pixels. Co-localization analysis (CD31 in combination with α SMA or α T): in every kidney section, at least three different small blood vessels were evaluated in an individual manner. The endothelial surface was quantified by counting the total number of red pixels (CD31). Yellow areas were also quantified, according to a defined color range. The color yellow reflected the respective marker of interest in endothelial cells, and the absolute number of yellow pixels was related to the absolute number of red pixels, respectively (results in percent). Kidney fibrosis was examined in formalin fixated, paraffin-embedded tissue sections after Masson trichrome staining. Endothelial expression of α SMA and α T was also analyzed in formalin fixated, paraffin-embedded tissue sections after deparaffinization, followed by incubation in 3% H₂O₂ for 10 minutes. After citrate-buffer treatment (microwave, 5 times for 3 minutes, pH 6.0), sections were stained with rat anti-mouse CD31 (PECAM-1—CloneSZ31, Dianova), and rabbit anti-Smooth Muscle Actin (EMELCA) or mouse anti- α

Tubulin (Abcam—ab24610) for primary incubation and with Alexa Fluor 488 goat anti-rabbit IgG (Dianova) and Alexa Fluor 594 goat anti-rat IgG (Dianova) or Alexa Fluor 488 anti-mouse IgG (Dianova) for secondary incubation, respectively. Primary incubation was performed overnight at 4°C while secondary incubation was performed for 1 hour at room temperature. To visualize the nuclei, tissue sections were counterstained with DAPI.

2.6. Quantification of Peritubular Capillary Density (PTCD). For PTCD quantification, exclusively cortical areas not containing glomeruli were documented. The total area of interest was evaluated for the absolute number of pixels. After CD31 staining (see Histology and Immunofluorescence Staining of Tissue Sections), the color red was quantified as described above and related to the total area of interest (red pixels as percentage of all pixels per area).

2.7. Quantification of Serum Cystatin C. Serum cystatin C levels were quantified using a commercially available kit (BioVendor, RD291009200R) according to the manufacturer's instructions.

2.8. PAC Isolation and Treatment for Proteomic Analyses. PACs from wildtype mice blood and spleen were isolated and expanded over 5-6 days of culture in EGM-2-medium (Lonza, CC-3156, CC-4176). Medium was aspirated and replaced by prewarmed 10 mL serum-free EGM-2-medium per 10 cm/dish. The serum-free EGM-2-medium was replaced by fresh medium 3 times, each incubation period lasting for 120 minutes in the presence of CO₂. Finally, the medium was replaced by FCS-free EGM-2 containing either Ang-2 (200 ng/ml) or BMP-5 (100 ng/ml). The treatment was carried out for 48 hours in an CO₂ incubator at 37°C. Subsequently, conditioned medium was collected and centrifuged at 300 g for 5 minutes at 4°C, and supernatants were collected and stored at -80°C.

2.9. Protein Precipitation and Concentration Estimation. To enrich the secretome proteins, the supernatants from control and treated PACs (10 ml each) were concentrated separately to 2 ml with a Vivaspin 20 Ultrafiltration Unit (Sartorius Göttingen, Germany). The resulting samples were then subjected to protein precipitation to reduce the volume and enrich the proteins. The precipitation was carried out by adding 3 volumes of ice-cold acetone containing 10% methanol and incubating overnight at -20°C. Precipitated proteins were pelleted by centrifugation at 12,000 g for 45 min at 4°C. The pellets were dried and resolved in urea buffer (30 mM Tris-HCl pH 8.5, 9.5 M urea, 2% CHAPS). The protein concentration was determined according to the Bradford method using BSA as the calibrator.

2.10. SDS-PAGE, Tryptic in Gel Digestion, and Mass Spectrometric Analysis of the PAC-Derived Secretome. The protein extracts from control sample and the different

treatments were separated in 1D-SDS-PAGE. The gels were stained with Coomassie blue and the visualized protein lanes were excised in 20-band section each and subjected to in gel digestion with trypsin (12.5 ng/ μ l). The resulting tryptic digests were extracted and analyzed using the Thermo Scientific Q Exactive. All MS/MS samples were analyzed using Mascot (Matrix Science, London, UK; version 2.4.1). Mascot was searched with a fragment ion mass tolerance of 0.020 Da and a parent ion tolerance of 10.0 PPM. Scaffold (version Scaffold_4.8.9), Proteome Software Inc., Portland, OR, was used to validate MS/MS based peptide and protein identifications. The software normalizes the MS/MS data between samples. This allows us to compare abundances of a protein between samples. The normalization scheme used works for the common experimental situation where individual proteins may be upregulated or downregulated, but the total amount of all proteins in each sample is about the same like it was the case in our experiments. Normalization is done on the MS sample level. The normalization method that scaffold uses is to sum the “unweighted spectrum counts” for each MS sample. These sums are then scaled so that they are all the same. The scaling factor for each sample is then applied to each protein group and adjusts its “unweighted spectrum count” to a normalized “quantitative value.”

2.11. Bioinformatic Analyses. To examine potential protein function categories and pathways of significantly regulated proteins, we performed bioinformatics analysis using the following public protein software: David Functional Annotation Bioinformatics Microarray Analysis (<http://david.abcc.ncifcrf.gov/>), the protein-protein interaction network software String 10.5 (<https://string-db.org>), and the pathway analysis software Kegg (<https://www.genome.jp/kegg/>).

2.12. Statistical Analyses. All results are given as mean $\pm$ SEM. The means of two groups were compared using Student's test. Differences between three or more groups were analyzed with the ANOVA test. Significance was postulated if the p value was below 0.05.

3. Results

Before the results will be presented, it needs to be stated that significant adverse events were not observed in any of the experimental groups. Therefore, no animals required euthanization before all analytes were collected.

3.1. PACs Release Microvesicles (MV). For microvesicle identification, several methods have been reported. One method involves staining of CD63 [22]. In this study, we decided to detect MV with a commercially available kit as reported in the Materials and Methods section. Three analyses were performed. The respective results were 4.6×10^8 , 3.4×10^8 , and 3.8×10^8 MV per sample (mean $\pm$ SEM 3.9×10^8).

3.2. PAC-Induced AKI Protection Is Mediated by MV, Derived from Native Cells. Control mice displayed mean serum cystatin C levels of 342 ± 20 ng/ml. Kidney function significantly deteriorated after ischemia (696 ± 26 ng/ml, $p < 0.0001$). Three distinct treatment strategies were defined: administration of either the secretome (SECR) or microvesicles (MV) alone or of SECR and MV combined. Both components were isolated either from native cells or from stimulated PACs. Since our previous studies showed substantial PAC agonistic effects of angiotensin-1/-2 [23, 24], bone morphogenetic protein-5 [25], and melatonin [8], we decided to utilize each of these four mediators in an individual series of experiments. Therefore, we performed a total number of 15 interventional groups. Whereas native SECR or SECR/MV in combination did not improve kidney function after ischemia (671 ± 26 and 630 ± 25 vs. 696 ± 26 ng/ml; $p = 0.5$ and $p = 0.08$), MV derived from unstimulated cells significantly lowered serum cystatin C levels (593 ± 17 vs. 696 ± 26 ng/ml; $p = 0.004$). Angiotensin-1 (Ang-1): PAC preconditioning with Ang-1 for 1 hour did not improve therapeutic effects of SECR or MV. On the contrary, if MV from stimulated cells were applied, kidney function declined even further (IRI + MV + Ang-1 and IRI + SECR + MV + Ang-1 vs. IRI 922 ± 34 and 875 ± 28 ng/ml vs. 696 ± 26 ng/ml; $p < 0.0001$ and $p = 0.0002$). Angiotensin-2 (Ang-2): Ang-2 stimulation did not result in any improvement or further deterioration of post-ischemic kidney function. The numerical results shall not be given in the text (see Figure 1). Bone Morphogenetic Protein-5 (BMP-5): PAC stimulation with BMP-5 aggravated AKI if MV were applied alone (IRI + MV-BMP-5 vs. IRI 799 ± 32 vs. 696 ± 26 ng/ml; $p = 0.02$). Melatonin: comparably to BMP-5, melatonin stimulation resulted in aggravation of AKI in the “IRI + MV + Mela” group (IRI + MV + Mela vs. IRI 872 ± 34 vs. 696 ± 26 ng/ml; $p = 0.0007$). The cystatin C results are summarized in Figure 1.

3.3. Early Mesenchymal Transdifferentiation of Endothelial Cells Is Attenuated by Native MV. AKI worsens the prognosis of respective subjects in the short and in the long term. The long-term prognosis critically depends on AKI-associated vascular rarefaction and interstitial fibrosis. The pathogenesis of latter is complex. However, mesenchymal transdifferentiation of endothelial cells (EndoMT) is commonly regarded as an essential fibrogenetic event [26]. We therefore aimed to evaluate endothelial expression of alpha-Smooth Muscle Actin (aSMA) early (48 hours) after ischemia. The results are given in percentages of the endothelial (CD31⁺) cell area (number of green pixels), covered by aSMA. In control mice, the mean percentage was 2.9 ± 0.8 . Post-ischemic animals (IRI) showed significantly higher values ($14.9 \pm 2.2\%$; $p = 0.0006$). Injection of the native SECR did not modulate endothelial aSMA in a significant manner ($18.4 \pm 0.9\%$; p value vs. “IRI” 0.17). The administration of native MV in contrast reduced endothelial aSMA (9.3 ± 1.2 vs. $14.9 \pm 2.2\%$; $p = 0.04$). If native SECR and MV were injected simultaneously, $11.2 \pm 0.6\%$ of the endothelial surface were covered by aSMA (p value vs. “IRI” 0.12). Regarding all other

FIGURE 1: Serum cystatin C in all control and experimental groups: the groups “Control,” “IRI” (ischemia reperfusion injury), “IRI + SECR” (secretome), “IRI + MV” (microvesicles), and “IRI + SECR + MV” are part of every panel (a–d). (a) The consequences of angiopoietin-1 (Ang-1) preconditioning; (b–d) the effects of angiopoietin-2 (Ang-2), melatonin (Mela), and bone morphogenetic protein-5 (BMP-5) preconditioning. * p value as compared to “Control” < 0.05 ; # p value as compared to “IRI” < 0.05 ; + p value as compared to “IRI + SECR” < 0.05 (results as means $\pm$ SEM).

interventional groups, only one significant difference occurred as compared to the “IRI” group: “IRI + SECR + MV + BMP-5” showed lower endothelial aSMA abundance (8.9 ± 0.9 vs. $14.9 \pm 2.2\%$; $p = 0.02$). Figure 2 summarizes the EndoMT analyses. In addition, we quantified interstitial matrix deposition in all groups after Masson trichrome staining as published previously [21, 27]. Matrix accumulation did not significantly differ between the control and any of the respective post-ischemic groups or between “IRI” and one or more of the interventional groups. We avoid mentioning numerical results in the text, but refer to Figure 3.

3.4. MV Administration Is Associated with Early Peritubular Capillary Rarefaction. Besides interstitial fibrosis, the loss of peritubular capillaries (peritubular capillary rarefaction) is a characteristic hallmark of progressive kidney disease. It frequently results from acute renal ischemia [28]. We evaluated the density of peritubular capillaries (PTCD) by relating the CD31+ area to the total view field. We exclusively analyzed the renal cortex and did not include glomeruli. Our analyses revealed comparable capillary densities in the control and in almost any of the interventional groups (Figure 4). The only difference occurred in post-ischemic

FIGURE 2: EndoMT-analyses. Comparing to Figure 1, every panel (a–d) contains the results of the following groups: “Control,” “IRI” (ischemia reperfusion injury), “IRI + SECR” (secretome), “IRI + MV” (microvesicles), and “IRI + SECR + MV,” respectively. (e–i) Representative images of small arteries/arterioles, stained for CD31 (red) and aSMA (green). The nuclei appear in blue. Magnified regions of e (j, k) and g (l, m). Magnifications: (e–i) $\times 40$; (j, l) $\sim \times 80$; (k, m) $\sim \times 120$. * p value as compared to “Control” < 0.05 ; #, p value as compared to “IRI” < 0.05 (results as means $\pm$ SEM).

animals that received either native MV alone or MV and SECR from unstimulated cells in combination. In these two groups, the PTCd was lower as compared to even control animals, respectively (MV $0.48 \pm 0.1\%$ and $0.51 \pm 0.1\%$ vs. $1.2 \pm 0.3\%$; $p = 0.04$ and $p = 0.03$). Figure 4 shows the data in detail.

3.5. Endothelial Alpha-Tubulin Abundances Do Not Vary Early after IRI. We previously discussed reduced endothelial alpha-tubulin (aT) expression to reflect an endogenous process of self-defense [21]. It needs however to be mentioned that respective analyses were performed several weeks after IRI (1, 4, and 6 weeks). In the current study, endothelial aT was exclusively quantified at 48 hours after ischemia. Endothelial alpha-tubulin did not significantly differ between the control and any of the respective post-ischemic groups or between “IRI” and one or more of the interventional groups (comparably to interstitial matrix accumulation-see above). We once again avoid mentioning numerical results in the text, but refer to Figure 5.

3.6. Proteomic Analysis of the PAC-Derived Secretome. To better explore the protective role of PACs, we investigated the alteration of the PAC-secretome under native and stimulated conditions. For this purpose, a deep proteomic investigation was performed. We generated secretomes from control, BMP-5 and Ang-2 treated PACs. The procedure including 1D-SDS-PAGE separation followed by in gel digestion and LC-MS/MS with spectral account quantification was carried out for each sample. In order to obtain a quick overview on the composition of the secretome, we plotted fold changes versus significance to generate volcano plots. This allowed a quick identification of secretome proteins that were significantly ($p < 0.05$) altered in their levels upon stimulation. Comparative presentation of the mass spectrometry data in Supplementary Table S1 allowed an overview on the large secretome alteration and the identification of a number of proteins that were only identified in the secretomes of Ang-2 or BMP-5 treated PACs.

As far as Ang-2 stimulated proteins were considered alone, the resulting interactome was highly complex (Figure 6(a)). The (expanded) pathway analysis however revealed a group of proteins that could be divided into five

FIGURE 3: Interstitial fibrosis, evaluated after Masson trichrome staining. (a–d) The results of the respective preconditioning groups, always compared with “Control,” “IRI” (ischemia reperfusion injury), “IRI + SECR” (secretome), “IRI + MV” (microvesicles), and “IRI + SECR + MV,” respectively. Interstitial matrix accumulation did not significantly differ at all between any of the groups. (e–h) (Magnification $\times 40$) representative images of four group (labelled). The rectangles in (f, g) surround areas of matrix deposition.

FIGURE 4: Peritubular capillary density (PTCD) of all groups. The PTCD surprisingly decreased if MV from native PACs were administered (either alone or in combination with the secretome). Other significant differences were missing. (a–d) The respective results of all preconditioning groups ((a) Ang-1; (b) Ang-2; (c) BMP-5; (d) melatonin). (e–g) Representative images of three groups (labelled) ((e–g) magnification $\times 40$; * p value as compared to “IRI” < 0.05 ; results as means $\pm$ SEM).

FIGURE 5: Endothelial alpha-tubulin expression in all groups. We did not detect any significant difference at all. (a–d) Illustration of the numerical results ((a) Ang-1; (b) Ang-2; (c) BMP-5; (d) melatonin). (e–g) Representative images of three groups (labelled, magnification $\times 40$); the white rectangles surround the magnified areas (e–g) (magnification $\times 160$); the white circles in (h–j) indicate the vessel of interest (results as means $\pm$ SEM).

main categories: extracellular matrix organization, innate immune system, neutrophil degranulation, metabolism, and immune system. Network analysis of the proteins, which secretion was inhibited upon Ang-2 treatment, resulted in a less complex secretome with proteins involved in the coagulation cascade and platelet activation (Figure 6(b)). BMP-5 treatment of PACs resulted in diminution of a large number of proteins that are principally involved in almost the same pathways (immune system, innate immune system, hemostasis, platelet degranulation, platelet activation, signaling, and aggregation) as found in the Ang-2 analyses (Figure 6(c)). The comparison of both, the Ang-2 and BMP-5 secretomes, showed upregulation of proteins involved in joint pathways (Figure 6(d)).

4. Discussion

The most intriguing findings in the current study were the exclusive improvement of post-ischemic kidney function after injecting MV from native cells and the complete lack of stimulatory effects of any of the four mediators on either MV or SECR. Two conclusions need to be drawn: MV substantially participate in mediating AKI protection, but cell-derived extracellular components are most likely not solely responsible for improving kidney dysfunction in acute situations.

In the past, we showed AKI protective effects of injected PACs in numerous experimental studies [8, 29, 30]. All protocols employed so far utilized intact cells, either without

FIGURE 6: Protein interaction networks between the proteins found to be differentially secreted upon treatments were generated using the protein networks software String (<https://string-db.org>). (a) Interaction network of the secretome proteins that were more than twofold secreted in Ang-2 treated cells compared to controls (ratio Agn-2/Ctr > 2). (b) Interaction network of proteins found to be downregulated (ratio Agn-2/Ctr < 0.5) under Ang-2 treatment compared to control. Interestingly, the interaction network showed that Ang-2 treatment resulted in decreased secretion of proteins involved in the coagulation cascade and in platelet activation (red and blue colored). (c) Interaction network of proteins, which level was downregulated (ratio BMP5/Ctr < 0.5) in secretome of BMP5 treated cells. (d) Interaction network of proteins highly secreted upon Ang-2 treatment compared to BMP5 treatment (ratio Ang-2/BMP5 > 2). The network revealed that Ang-2 treatment resulted in significant alteration of EPC secretome.

or after pharmacological preconditioning. Over the years, we identified several mediators that substantially improved the cells' therapeutic competence in AKI [8, 23, 24]. The current study, which avoided the injection of living cells, did not confirm any of these observations. Thus, we must conclude that the mere presence of cells within the kidney is important for PAC-associated kidney protection, particularly under circumstances when preconditioning protocols are being applied. The field of PAC(EPC)-mediated AKI protection substantially benefitted from studies by Cantaluppi and colleagues [10] who identified the critical role of cell-derived microvesicles (MV) in IRI. Not only did the authors prove that AKI may be prevented by injecting MV alone but they

also extracted certain microRNA molecules from the vesicular fraction. By RNA depletion prior to MV administration, protective effects of the vesicles vanished. The discussion about cellular mechanisms responsible for tissue protection not only in AKI and not only regarding PACs has been going on for a long time. In 2003, Rehman et al. showed that supernatants from cultured EPCs are significantly enriched by angiogenic growth factors such as vascular endothelial growth factor, hepatocyte growth factor, and granulocyte colony-stimulating factor, and by granulocyte-macrophage colony-stimulating factor [19]. Since then, cell effects were thought to substantially occur in an indirect manner. In subsequent years, proteomic analyses revealed

additional humoral mediators including thymidine phosphorylase, matrix metalloproteinase 9, IL-8, pre-B cell enhancing factor, and macrophage migration inhibitory factor [31, 32]. Thus, the concept of the “secretome” evolved. The profound modulatory role of the secretome was highlighted by studies of Goligorsky’s group. In a 2015 published article, EPC-/MSC- (mesenchymal stem cell-) derived cytokines substantially influenced the phenotype and biological behavior of macrophages [33]. It was concluded that the secretome partly mediates protection from LPS-induced AKI. Later studies showed that endothelium-derived humoral factors are also involved in renal fibrogenesis [34]. In the 2015 published article [33], one essential problem related to any cell-based therapeutic approach in AKI was emphasized: the problem of cell delivery. Therefore, MV appear as a promising option at first sight, although the problem of ex vivo generation of such highly complex structures would have to be solved. In addition, our analyses did not exclusively show beneficial end point effects of MV. For instance, cystatin C levels increased and anti-mesenchymal effects vanished if MV from preconditioned cells (Ang-1, Mela, BMP-5) were applied. Finally, MV from native PACs significantly affected the vascular structure despite the fact that excretory function was improved.

In the last paragraph, we would like to discuss our proteomic data. Only a few studies evaluated the role and composition of the secretome derived from the so-called endothelial progenitor cells (here: PACs) in the past. In one study, published in 2015 [33], hydrogel-embedded EPCs were subcutaneously implanted in LPS-treated mice, resulting in AKI protection under specific circumstances. While the study addressed systemic cytokine levels in the animals, the authors did not acquire data on the secretome per se. It was however concluded that paracrine actions of (embedded) EPCs most likely mediate biological cell effects. The possibility of MV-dependent activity was not discussed at all. A 2018 published investigation analyzed the EPC secretome in the context of oligodendrocyte repair [35]. The authors performed a detailed proteomic study and identified a heterogeneous group of proteins excreted by the cells. Among those were angiogenin, stromal derived factor-1 (SDF-1), platelet-derived growth factor, vascular endothelial growth factor-B (VEGF-B), and several matrix metalloproteinases (MMP). Thus, they detected mediators with substantial proangiogenic activity. The third study that needs to be mentioned focused on EPC secretome-enriched nanoparticles in vascular repair [36]. It was documented that hypoxia stimulated the production of secretome proteins with angiogenic properties. Contrasting to these reports, our analyses revealed enrichment of mediators involved in the coagulation cascade and platelet activation. Significant stimulatory effects on angiogenic proteins did not become apparent. The discrepant findings possibly result from the artificial conditions that were used in our investigation. Felice and colleagues [36] exposed the cells to hypoxic conditions while we subjected PACs to specific mediators that were shown to significantly increase the AKI protective activity of intact cells [8, 23–25]. Regarding the fact that our study failed to show any beneficial effects of the secretome at

all, the data substantially indicate that renoprotective effects of whole cells most likely require the mere presence of intact PACs in the kidney, especially if preconditioning protocols are in use.

Together, our data show that PAC-mediated AKI protection substantially depends on the availability of cell-derived EV. However, since previous data showed improved AKI-protection by PACs after cell preconditioning with certain mediators (Ang-1 and -2, melatonin, BMP-5), mechanisms other than exclusively vesicle-dependent mechanisms must be involved in PAC-mediated AKI protection.

Data Availability

All data are available upon request to the corresponding author (d.patschan@klinikum-brandenburg.de).

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

HD performed all proteomic analyses and corrected the manuscript; KS performed all surgical procedures and the histological analyses; SP analyzed data and corrected the manuscript; GAM corrected the manuscript and provided laboratory space; OR provided financial support and corrected the manuscript; MZ helped with additional studies on CD63 detection; DP designed the study, received funding, and wrote the manuscript.

Acknowledgments

The study was supported by the Deutsche Forschungsgemeinschaft (DFG) (Grant recipient: DP (PA1530/8-1)).

Supplementary Materials

Supplementary Table S1: proteomic analyzes in detail. The table shows results for the following stimulatory conditions: Angi/Ctro (angiotensin-2 in relation to controls), only in AngII (angiotensin-2 only), BMP5/Ctr (bone morphogenetic protein-5 in relation to controls), AngII/Bmp5 (angiotensin-2 in relation to bone morphogenetic protein-5). (*Supplementary Materials*)

References

- [1] A. Bienholz, B. Wilde, and A. Kribben, “From the nephrologist’s point of view: diversity of causes and clinical features of acute kidney injury,” *Clinical Kidney Journal*, vol. 8, no. 4, pp. 405–414, 2015.
- [2] M. Heeg, A. Mertens, D. Ellenberger, G. A. Müller, and P. Daniel, “Prognosis of AKI in malignant diseases with and without sepsis,” *BMC Anesthesiol*, vol. 13, p. 36, 2013.
- [3] A. J. Peired, A. Sisti, and P. Romagnani, “Mesenchymal stem cell-based therapy for kidney disease: a review of clinical

- evidence," *Stem Cells International*, vol. 2016, Article ID 4798639, 22 pages, 2016.
- [4] J. Yu, M. A. Vodyanik, K. Smuga-Otto et al., "Induced pluripotent stem cell lines derived from human somatic cells," *Science*, vol. 318, no. 5858, pp. 1917–1920, 2007.
 - [5] P.-Y. Lee, Y. Chien, G.-Y. Chiou, C.-H. Lin, C.-H. Chiou, and D.-C. Tarn, "Induced pluripotent stem cells without c-Myc attenuate acute kidney injury via downregulating the signaling of oxidative stress and inflammation in ischemia-reperfusion rats," *Cell Transplantation*, vol. 21, no. 12, pp. 2569–2585, 2012.
 - [6] Q. Li, S.-F. Tian, Y. Guo et al., "Transplantation of induced pluripotent stem cell-derived renal stem cells improved acute kidney injury," *Cell and Bioscience*, vol. 5, p. 45, 2015.
 - [7] D. P. Basile, J. A. Collett, and M. C. Yoder, "Endothelial colony-forming cells and pro-angiogenic cells: clarifying definitions and their potential role in mitigating acute kidney injury," *Acta Physiologica*, vol. 222, no. 2, Article ID e12914, 2017.
 - [8] D. Patschan, A. Hildebrandt, J. Rinneburger et al., "The hormone melatonin stimulates renoprotective effects of "early outgrowth" endothelial progenitor cells in acute ischemic kidney injury," *American Journal of Physiology-Renal Physiology*, vol. 302, no. 10, pp. F1305–F1312, 2012.
 - [9] D. Patschan, I. Buschmann, O. Ritter, and A. Kribben, "Cell-based therapies in acute kidney injury (AKI)," *Kidney and Blood Pressure Research*, vol. 43, no. 3, pp. 673–681, 2018.
 - [10] V. Cantaluppi, S. Gatti, D. Medica et al., "Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells," *Kidney International*, vol. 82, no. 4, pp. 412–427, 2012.
 - [11] S. Bruno, C. Grange, F. Collino et al., "Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury," *PLoS One*, vol. 7, no. 3, Article ID e33115, 2012.
 - [12] Y. Zhou, H. Xu, W. Xu et al., "Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro," *Stem Cell Research & Therapy*, vol. 4, no. 2, p. 34, 2013.
 - [13] M. Sanchez, S. Bruno, C. Grange et al., "Human liver stem cells and derived extracellular vesicles improve recovery in a murine model of acute kidney injury," *Stem Cell Research & Therapy*, vol. 5, no. 6, p. 124, 2014.
 - [14] F. Collino, S. Bruno, D. Incarnato et al., "AKI recovery induced by mesenchymal stromal cell-derived extracellular vesicles carrying MicroRNAs," *Journal of the American Society of Nephrology*, vol. 26, no. 10, pp. 2349–2360, 2015.
 - [15] D. Burger, J. L. Viñas, S. Akbari et al., "Human endothelial colony-forming cells protect against acute kidney injury: role of exosomes," *The American Journal of Pathology*, vol. 185, no. 8, pp. 2309–2323, 2015.
 - [16] G. Zhang, X. Zou, Y. Huang et al., "Mesenchymal stromal cell-derived extracellular vesicles protect against acute kidney injury through anti-oxidation by enhancing Nrf2/ARE activation in rats," *Kidney and Blood Pressure Research*, vol. 41, no. 2, pp. 119–128, 2016.
 - [17] A. Ranghino, S. Bruno, B. Bussolati et al., "The effects of glomerular and tubular renal progenitors and derived extracellular vesicles on recovery from acute kidney injury," *Stem Cell Research and Therapy*, vol. 8, no. 1, p. 24, 2017.
 - [18] X. Yuan, D. Li, X. Chen et al., "Extracellular vesicles from human-induced pluripotent stem cell-derived mesenchymal stromal cells (hiPSC-MSCs) protect against renal ischemia/reperfusion injury via delivering specificity protein (SP1) and transcriptional activating of sphingosine kinase 1 and inhibiting necroptosis," *Cell Death & Disease*, vol. 8, no. 12, p. 3200, 2017.
 - [19] J. Rehman, J. Li, C. M. Orschell, and K. L. March, "Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors," *Circulation*, vol. 107, no. 8, pp. 1164–1169, 2003.
 - [20] C. Théry, K. W. Witwer, E. Aikawa et al., "Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines," *Journal of Extracellular Vesicles*, vol. 7, no. 1, Article ID 1535750, 2018.
 - [21] D. Patschan, K. Schwarze, E. Henze, S. Patschan, and G. A. Müller, "The endothelial-to-mesenchymal transition and endothelial cilia in EPC-mediated postischemic kidney protection," *American Journal of Physiology-Renal Physiology*, vol. 310, no. 7, pp. F679–F687, 2016.
 - [22] L. Le Gall, Z. G. Ouandaogo, E. Anakor et al., "Optimized method for extraction of exosomes from human primary muscle cells," *Skeletal Muscle*, vol. 10, no. 1, p. 20, 2020.
 - [23] D. Patschan, R. Backhaus, H. J. Elle et al., "Angiopoietin-2 modulates eEOC-mediated renoprotection in AKI in a dose-dependent manner," *Journal of Nephrology*, vol. 26, no. 4, pp. 667–674, 2013.
 - [24] D. Patschan, J. Rinneburger, N. Idrizi et al., "Angiopoietin-1 treated early endothelial outgrowth cells (eEOCs) are activated in vitro and reduce renal damage in murine acute ischemic kidney injury (iAKI)," *BMC Nephrology*, vol. 14, p. 227, 2013.
 - [25] D. Patschan, K. Schwarze, A. Lange et al., "Bone morphogenetic protein-5 and early endothelial outgrowth cells (eEOCs) in acute ischemic kidney injury (AKI) and 5/6-chronic kidney disease," *American Journal of Physiology-Renal Physiology*, vol. 305, no. 3, pp. F314–F322, 2013.
 - [26] M. Zeisberg and R. Kalluri, "Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis," *American Journal of Physiology-Cell Physiology*, vol. 304, no. 3, pp. C216–C225, 2013.
 - [27] D. Patschan, K. Schwarze, B. Tampe, M. Zeisberg, S. Patschan, and G. A. Müller, "Endothelial Colony Forming Cells (ECFCs) in murine AKI-implications for future cell-based therapies," *BMC Nephrology*, vol. 18, no. 1, p. 53, 2017.
 - [28] M. S. Goligorsky, "Microvascular rarefaction: the decline and fall of blood vessels," *Organogenesis*, vol. 6, no. 1, pp. 1–10, 2010.
 - [29] D. Patschan, K. Krupinca, S. Patschan, Z. Zhang, C. Hamby, and M. S. Goligorsky, "Dynamics of mobilization and homing of endothelial progenitor cells after acute renal ischemia: modulation by ischemic preconditioning," *American Journal of Physiology-Renal Physiology*, vol. 291, no. 1, pp. F176–F185, 2006.
 - [30] D. Patschan, S. Patschan, G. G. Gobe, S. Chintala, and M. S. Goligorsky, "Uric acid heralds ischemic tissue injury to mobilize endothelial progenitor cells," *Journal of the American Society of Nephrology*, vol. 18, no. 5, pp. 1516–1524, 2007.
 - [31] M. S. Goligorsky, K. Yasuda, and B. Ratliff, "Dysfunctional endothelial progenitor cells in chronic kidney disease," *Journal of the American Society of Nephrology*, vol. 21, no. 6, pp. 911–919, 2010.
 - [32] G. Pula, U. Mayr, C. Evans et al., "Proteomics identifies thymidine phosphorylase as a key regulator of the angiogenic

- potential of colony-forming units and endothelial progenitor cell cultures,” *Circulation Research*, vol. 104, no. 1, pp. 32–40, 2009.
- [33] J. A. Zullo, E. P. Nadel, M. M. Rabadi et al., “The secretome of hydrogel-coembedded endothelial progenitor cells and mesenchymal stem cells instructs macrophage polarization in endotoxemia,” *Stem Cells Translational Medicine*, vol. 4, no. 7, pp. 852–861, 2015.
- [34] M. Lipphardt, H. Dihazi, N. L. Jeon et al., “Dickkopf-3 in aberrant endothelial secretome triggers renal fibroblast activation and endothelial-mesenchymal transition,” *Nephrology Dialysis Transplantation*, vol. 34, no. 1, pp. 49–62, 2019.
- [35] T. Maki, A. Morancho, P. Martinez-San Segundo et al., “Endothelial progenitor cell secretome and oligovascular repair in a mouse model of prolonged cerebral hypoperfusion,” *Stroke*, vol. 49, no. 4, pp. 1003–1010, 2018.
- [36] F. Felice, A. M. Piras, S. Rocchiccioli et al., “Endothelial progenitor cell secretome delivered by novel polymeric nanoparticles in ischemic hindlimb,” *International Journal of Pharmaceutics*, vol. 542, no. 1-2, pp. 82–89, 2018.